Viveve Medical, Inc. designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories. It markets its products through sales employees and distributors in the United States, the Asia Pacific, Europe, the Middle East, Latin America, and Canada. Viveve Medical, Inc. was founded in 2005 and is headquartered in Englewood, Colorado.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Electromedical equipment
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VIVE
CUSIPN/A
Phone720-696-8100
Debt
Debt-to-Equity Ratio3.42
Current Ratio4.41
Quick Ratio4.00
Price-To-Earnings
Trailing P/E Ratio-1.64
Forward P/E Ratio-2.28
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.29 million
Price / Sales7.11
Cash FlowN/A
Price / CashN/A
Book Value($0.13) per share
Price / Book-26.54
Profitability
EPS (Most Recent Fiscal Year)($2.11)
Net Income$-36,950,000.00
Net Margins-239.33%
Return on Equity-551.85%
Return on Assets-100.83%
Miscellaneous
Employees103
Outstanding Shares31,490,000
Market Cap$84.39 million
Viveve Medical (NASDAQ:VIVE) Frequently Asked Questions
What is Viveve Medical's stock symbol?
Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."
How were Viveve Medical's earnings last quarter?
Viveve Medical Inc (NASDAQ:VIVE) issued its quarterly earnings results on Thursday, August, 9th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.38) by $0.01. The company earned $5.53 million during the quarter, compared to analyst estimates of $4.97 million. Viveve Medical had a negative net margin of 239.33% and a negative return on equity of 551.85%. View Viveve Medical's Earnings History.
When is Viveve Medical's next earnings date?
What price target have analysts set for VIVE?
7 brokers have issued twelve-month price targets for Viveve Medical's shares. Their predictions range from $6.00 to $11.00. On average, they anticipate Viveve Medical's share price to reach $9.20 in the next year. This suggests a possible upside of 166.7% from the stock's current price. View Analyst Price Targets for Viveve Medical.
What is the consensus analysts' recommendation for Viveve Medical?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Viveve Medical in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Viveve Medical.
What are Wall Street analysts saying about Viveve Medical stock?
Here are some recent quotes from research analysts about Viveve Medical stock:
- 1. Mizuho analysts commented, "We expect the trends in utilization and pricing to continue in 2018. FDA Approval of IDE to Conduct VIVEVE2 Clinical Trial. The FDA approved Viveve’s IDE to conduct a sexual function study in the U.S. The study is expected to start in 2Q18 and will include approximately 250 patients across 25 clinical sites in the U.S. and Canada. The primary endpoint will measure the mean change from baseline in the total FSFI (Female Sexual Function Index) at 12 months. Data from the study is expected in 2H19. Cash Position and Upcoming Catalysts. Viveve’s current cash position stands at approximately $55.7 mil following a recent $35.0 mil equity offering in February." (3/20/2018)
- 2. Maxim Group analysts commented, "4Q17 revenue of $5.1M, up 108% y/y, was inline with the preannouncement." (3/16/2018)
Who are some of Viveve Medical's key competitors?
Some companies that are related to Viveve Medical include BioLife Solutions (BLFS), Vision Sciences (CGNT), Semler Scientific (SMLR), Rockwell Medical (RMTI), Helius Medical Technologies (HSDT), Fonar (FONR), Second Sight Medical Products (EYES), Zynex (ZYXI), Edap Tms (EDAP), IRIDEX (IRIX), Stereotaxis (STXS), Soleno Therapeutics (SLNO), Digirad (DRAD), Nexeon Medsystems (NXNND) and Aradigm (ARDM).
Who are Viveve Medical's key executives?
Viveve Medical's management team includes the folowing people:
- Mr. Scott C. Durbin, CEO, Sec. & Director (Age 49)
- Mr. James Gregory Atkinson, Chief Bus. Officer & Pres (Age 60)
- Ms. Deborah A. Jorn, Sr. Advisor to the CEO & Director (Age 60)
- Mr. Jim B. Robbins, VP of Fin. & Admin. and Principal Accounting Officer (Age 54)
- Mr. Martin Kerber, VP of Operations
When did Viveve Medical IPO?
(VIVE) raised $13 million in an initial public offering on Tuesday, June 14th 2016. The company issued 1,600,000 shares at $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.
How do I buy shares of Viveve Medical?
Shares of VIVE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Viveve Medical's stock price today?
One share of VIVE stock can currently be purchased for approximately $3.45.
How big of a company is Viveve Medical?
Viveve Medical has a market capitalization of $84.39 million and generates $15.29 million in revenue each year. The company earns $-36,950,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Viveve Medical employs 103 workers across the globe.
What is Viveve Medical's official website?
How can I contact Viveve Medical?
Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]
MarketBeat Community Rating for Viveve Medical (NASDAQ VIVE)
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe VIVE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIVE will underperform the S&P 500 over the long term. You may vote once every thirty days.
